Kodiak Sciences' Zenkuda Achieves 62.5% Response Rate in Phase 3 GLOW2 Diabetic Retinopathy Trial
核心洞察
Kodiak Sciences' Zenkuda (搜索) demonstrated 62.5% of patients achieved ≥2-step improvement in diabetic retinopathy (搜索) severity score versus 3.3% with sham control (p<0.0001) in the Phase 3 GLOW2 confirmatory study.
The treatment showed an 85% risk reduction in developing sight-threatening complications such as proliferative diabetic retinopathy (搜索) or diabetic macular edema (搜索) compared to sham control.
Zenkuda (搜索) maintained an exceptional safety profile with zero cases of intraocular inflammation, retinal vasculitis, or occlusive retinal vasculitis reported throughout the study.
Kodiak Sciences announced overwhelmingly positive topline results from its Phase 3 GLOW2 study evaluating Zenkuda (搜索) (tarcocimab tedromer) in patients with diabetic retinopathy (搜索), with the treatment demonstrating superior efficacy and an exceptional safety profile that positions the company for regulatory submission.
The GLOW2 study, a prospective, randomized, double-masked, sham-controlled multicenter trial, met its primary endpoint with high statistical significance. A total of 62.5% of patients treated with Zenkuda (搜索) achieved a ≥2-step improvement in the Diabetic Retinopathy (搜索) Severity Score (DRSS) at Week 48, compared to only 3.3% in the sham-control group (p<0.0001).
Robust Efficacy Across Multiple Endpoints
The study demonstrated Zenkuda (搜索)'s superiority across all key secondary endpoints. Most notably, the treatment showed an 85% risk reduction in developing prespecified sight-threatening complications, including new or worsening proliferative diabetic retinopathy (搜索) or center-involving diabetic macular edema (搜索), compared to sham through Week 48 (2.4% with Zenkuda versus 15.8% with sham, p=0.0001).
Additionally, 13.7% of patients on Zenkuda (搜索) achieved a ≥3-step improvement in DRSS versus 0% with sham (p<0.0001), demonstrating the treatment's ability to achieve substantial disease improvement in a meaningful proportion of patients.
The GLOW2 study was designed as a confirmatory trial to replicate and extend findings from the positive pivotal GLOW1 study. Unlike GLOW1, GLOW2 expanded the patient population to include those with proliferative diabetic retinopathy (搜索) and mild diabetic macular edema (搜索), alongside patients with moderately severe to severe diabetic retinopathy (搜索).
Extended Dosing Interval Achieved
Patients in GLOW2 received Zenkuda (搜索) via intravitreal injection at progressively extended intervals after a loading phase, with all patients achieving six-month dosing by the end of the study. The dosing schedule included injections at baseline, Week 4, Week 8, Week 20, and Week 44, representing five injections in the first year.
Dr. Charles Wykoff, Chairman of Research at Retina Consultants of America and Professor of Clinical Ophthalmology at Blanton Eye Institute, Houston Methodist Hospital, emphasized the clinical significance of these results. "GLOW2 is unique among registration trials targeting an approval for DR by intentionally including eyes with center-involved DME and proliferative DR. Among this higher-risk population, Zenkuda (搜索) showed strong efficacy while incorporating a 6-month treatment interval after three monthly injections, supporting flexible dosing as may be clinically indicated."
Exceptional Safety Profile Maintained
Zenkuda (搜索) demonstrated an exceptional safety profile throughout the study. Notably, no cases of intraocular inflammation were reported, and no cases of retinal vasculitis or occlusive retinal vasculitis were observed. The incidence of cataract in the study eye was low at 2.3% with Zenkuda versus 1.6% with sham, remaining in line with expected background rates in patients with diabetic retinopathy (搜索).
Real-World Patient Population Considerations
The study included patients using GLP-1 medications, reflecting real-world diabetic patient populations. GLP-1 use was well-balanced between treatment arms (46.1% in the Zenkuda (搜索) arm and 42.4% in the sham arm). Among patients using GLP-1 medications, Zenkuda achieved a ≥2-step improvement in DRSS from baseline to Week 48 in 60.0% of patients compared with 64.3% in patients not using GLP-1 medications, demonstrating consistent efficacy regardless of concomitant GLP-1 use.
Regulatory and Commercial Implications
Dr. Victor Perlroth, Chief Executive Officer of Kodiak Sciences, stated, "We now have a multi-indication BLA-ready profile for Zenkuda (搜索), and we intend to accelerate our BLA submission plans." The GLOW2 study was the first Phase 3 trial to test Zenkuda's enhanced commercial formulation, which combines free (unconjugated) and conjugated protein in a single biologic.
The positive results from GLOW2, combined with previous successful Phase 3 studies including GLOW1 in diabetic retinopathy (搜索), BEACON in retinal vein occlusion (搜索), and DAYLIGHT in wet age-related macular degeneration (搜索), provide Kodiak with a comprehensive regulatory package for multiple indications.
Market Impact and Future Outlook
The announcement triggered significant market response, with Kodiak Sciences' stock surging 19% in heavy trading, reaching $22.75 and reflecting renewed investor confidence in the company's Antibody Biopolymer Conjugate (ABC) platform.
Looking ahead, Kodiak continues to advance its pipeline with the ongoing Phase 3 DAYBREAK study in wet AMD, with topline results expected in the third quarter of 2026. The company is also developing KSI-501, a bispecific anti-IL-6, VEGF (搜索) trap ABC biologic, and KSI-101 for macular edema secondary to inflammation (搜索), with multiple Phase 3 readouts anticipated throughout 2026.
Dr. J. Pablo Velazquez-Martin, Chief Medical Officer of Kodiak Sciences, noted the consistency of the results: "We are very pleased to see that GLOW2 demonstrated a high degree of internal consistency across all datapoints. Importantly, GLOW2 also demonstrated strong external consistency when contextualized with GLOW1. Taken together, the combined GLOW1 and GLOW2 data package speaks volumes about the robustness of the data."